AU2016285727B9 - Biomarkers for nanoparticle compositions - Google Patents

Biomarkers for nanoparticle compositions Download PDF

Info

Publication number
AU2016285727B9
AU2016285727B9 AU2016285727A AU2016285727A AU2016285727B9 AU 2016285727 B9 AU2016285727 B9 AU 2016285727B9 AU 2016285727 A AU2016285727 A AU 2016285727A AU 2016285727 A AU2016285727 A AU 2016285727A AU 2016285727 B9 AU2016285727 B9 AU 2016285727B9
Authority
AU
Australia
Prior art keywords
mtor
individual
activating aberration
cancer
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016285727A
Other languages
English (en)
Other versions
AU2016285727A1 (en
AU2016285727B2 (en
Inventor
Neil P. Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Publication of AU2016285727A1 publication Critical patent/AU2016285727A1/en
Application granted granted Critical
Publication of AU2016285727B2 publication Critical patent/AU2016285727B2/en
Publication of AU2016285727B9 publication Critical patent/AU2016285727B9/en
Priority to AU2021290200A priority Critical patent/AU2021290200B2/en
Priority to AU2024204661A priority patent/AU2024204661A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2016285727A 2015-06-29 2016-06-29 Biomarkers for nanoparticle compositions Active AU2016285727B9 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021290200A AU2021290200B2 (en) 2015-06-29 2021-12-20 Biomarkers for nanoparticle compositions
AU2024204661A AU2024204661A1 (en) 2015-06-29 2024-07-05 Biomarkers for nanoparticle compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186309P 2015-06-29 2015-06-29
US62/186,309 2015-06-29
PCT/US2016/040196 WO2017004264A1 (en) 2015-06-29 2016-06-29 Biomarkers for nanoparticle compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021290200A Division AU2021290200B2 (en) 2015-06-29 2021-12-20 Biomarkers for nanoparticle compositions

Publications (3)

Publication Number Publication Date
AU2016285727A1 AU2016285727A1 (en) 2018-02-01
AU2016285727B2 AU2016285727B2 (en) 2021-09-23
AU2016285727B9 true AU2016285727B9 (en) 2021-09-30

Family

ID=57609078

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016285727A Active AU2016285727B9 (en) 2015-06-29 2016-06-29 Biomarkers for nanoparticle compositions
AU2021290200A Active AU2021290200B2 (en) 2015-06-29 2021-12-20 Biomarkers for nanoparticle compositions
AU2024204661A Pending AU2024204661A1 (en) 2015-06-29 2024-07-05 Biomarkers for nanoparticle compositions

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021290200A Active AU2021290200B2 (en) 2015-06-29 2021-12-20 Biomarkers for nanoparticle compositions
AU2024204661A Pending AU2024204661A1 (en) 2015-06-29 2024-07-05 Biomarkers for nanoparticle compositions

Country Status (10)

Country Link
US (3) US20180177771A1 (enExample)
EP (1) EP3313381A4 (enExample)
JP (4) JP2018527308A (enExample)
KR (2) KR20240144442A (enExample)
AU (3) AU2016285727B9 (enExample)
CA (1) CA2990703C (enExample)
HK (1) HK1254398A1 (enExample)
IL (2) IL312318A (enExample)
MX (2) MX2017016519A (enExample)
WO (1) WO2017004264A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5933893B2 (ja) 2006-12-14 2016-06-15 アブラクシス バイオサイエンス， エルエルシー ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法
ME03596B (me) 2009-04-15 2020-07-20 Abraxis Bioscience Llc Kompozicije nanočesтica bez priona i postupci povezani sa njima
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
KR101970342B1 (ko) 2011-04-28 2019-04-18 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
EP3560486A1 (en) 2011-12-14 2019-10-30 Abraxis BioScience, LLC Use of polymeric excipients for lyophilization or freezing of particles
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CA2903454A1 (en) 2013-03-12 2014-10-02 Abraxis Bioscience, Llc Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
EA036790B1 (ru) 2015-06-29 2020-12-22 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способ лечения злокачественной пекомы
WO2019140257A1 (en) * 2018-01-11 2019-07-18 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for characterizing and treating prostate cancer
EP3768268A4 (en) * 2018-03-20 2022-02-23 Abraxis BioScience, LLC METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE
KR20210024471A (ko) * 2018-05-22 2021-03-05 아브락시스 바이오사이언스, 엘엘씨 폐고혈압을 치료하기 위한 방법 및 조성물
CN111187834B (zh) * 2019-01-08 2021-01-22 中国科学院上海营养与健康研究所 胃肠道间质瘤的靶点depdc5及其在诊断和治疗中的应用
CN120267635A (zh) * 2019-03-19 2025-07-08 阿布拉科斯生物科学有限公司 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病
EP4051241A4 (en) 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN
MX2022005715A (es) * 2019-11-11 2022-09-19 Abraxis Bioscience Llc Biomarcadores para composiciones de nanoparticulas.
AU2021358768A1 (en) * 2020-10-06 2023-05-18 The Regents Of The University Of Colorado, A Body Corporate Subject-specific treatments for venetoclax-resistant acute myeloid leukemia
WO2022186673A1 (ko) * 2021-03-05 2022-09-09 전남대학교산학협력단 차세대 염기서열분석 기반 표적유전자 rna 염기서열 분석 패널 및 분석알고리즘
WO2024215799A1 (en) * 2023-04-11 2024-10-17 Leapfrog Bio, Inc. Pi3k inhibitors for the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2014151853A1 (en) * 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153009A1 (en) * 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
KR20190002733A (ko) * 2010-12-30 2019-01-08 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
EP2971122B1 (en) * 2013-03-15 2020-08-26 Memorial Sloan Kettering Cancer Center Biomarkers for response to rapamycin analogs
US20180153863A1 (en) * 2015-06-29 2018-06-07 Abraxis Bioscience, Llc Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2014151853A1 (en) * 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
G. G. MALOUF ET AL, Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network, ANNALS OF ONCOLOGY, NL, (2010-2-12), vol 21, no 9, ISSN 0923-7534, pg1834-1838 *
INOKI, K et al., "TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling", Nat Cell Biol, (2002-08-12), vol. 4, pages 648–657 *
JANKU, F et al., "Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors", Cell Reports., (2014-01-30), vol. 6, no. 2, pages 377 - 387 *

Also Published As

Publication number Publication date
IL256326B1 (en) 2024-05-01
IL312318A (en) 2024-06-01
IL256326B2 (en) 2024-09-01
US20250152563A1 (en) 2025-05-15
CA2990703C (en) 2024-04-30
KR20240144442A (ko) 2024-10-02
CA2990703A1 (en) 2017-01-05
EP3313381A4 (en) 2019-02-27
US20230080409A1 (en) 2023-03-16
WO2017004264A1 (en) 2017-01-05
KR102708679B1 (ko) 2024-09-24
AU2024204661A1 (en) 2024-07-25
MX2017016519A (es) 2018-08-16
MX2023013010A (es) 2023-11-15
IL256326A (en) 2018-02-28
AU2016285727A1 (en) 2018-02-01
HK1254398A1 (zh) 2019-07-19
US20180177771A1 (en) 2018-06-28
JP2018527308A (ja) 2018-09-20
KR20180019230A (ko) 2018-02-23
AU2021290200B2 (en) 2024-05-02
EP3313381A1 (en) 2018-05-02
JP2023071656A (ja) 2023-05-23
AU2021290200A1 (en) 2022-01-20
AU2016285727B2 (en) 2021-09-23
JP2025097987A (ja) 2025-07-01
JP2021169457A (ja) 2021-10-28

Similar Documents

Publication Publication Date Title
AU2021290200B2 (en) Biomarkers for nanoparticle compositions
US12133844B2 (en) Methods of treating epithelioid cell tumors
JP2018527308A5 (enExample)
US20240009323A1 (en) Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy
HK40074948A (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
HK40074948B (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
HK1247094B (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)